Edmond DE Rothschild Holding S.A. Makes New Investment in Biogen Inc. $BIIB

Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 56,064 shares of the biotechnology company’s stock, valued at approximately $12,113,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Reflection Asset Management purchased a new position in shares of Biogen in the 4th quarter valued at approximately $25,000. WPG Advisers LLC grew its stake in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the period. Bell Investment Advisors Inc bought a new position in Biogen in the second quarter worth $27,000. First Horizon Corp bought a new position in Biogen in the fourth quarter worth $30,000. Finally, WFA of San Diego LLC purchased a new position in Biogen during the second quarter valued at $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BIIB. Evercore initiated coverage on shares of Biogen in a research report on Friday, May 15th. They issued an “outperform” rating on the stock. UBS Group lifted their price target on shares of Biogen from $225.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Canaccord Genuity Group boosted their price objective on shares of Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Rothschild & Co Redburn raised their target price on shares of Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Finally, Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biogen presently has a consensus rating of “Moderate Buy” and an average price target of $227.07.

Biogen Price Performance

BIIB opened at $221.56 on Thursday. The stock has a 50-day moving average price of $204.91 and a 200-day moving average price of $194.08. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The firm has a market cap of $32.74 billion, a PE ratio of 39.21, a P/E/G ratio of 6.62 and a beta of 0.17. Biogen Inc. has a 1 year low of $131.52 and a 1 year high of $222.15.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. Biogen’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the prior year, the firm posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts predict that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.